Internal Medicine, Endocrinology, Diabetes, & Metabolism · Kokomo, IN
NPI
1487096129
Since 2013
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3509 S Reed Rd
Kokomo, IN, 46902
Phone (765) 776-8550
Groups this clinician bills Medicare through
Medicare paid, 2024
$101K
3,160 services
Medicare patients, 2024
400
Average age 71
Drug cost, 2024
$4.5M
7,849 prescriptions
Company payments, 2025
$118
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paula Szczepanczyk was code J0897 (injection, denosumab, 1 mg), 1,260 times for 12 patients. In total Paula Szczepanczyk billed 3,160 services in 15 codes, and Medicare paid $101K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-08-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,260 | 12 | $20.55 | $26K |
| 99214 Office E&M - Established | Office | 647 | 369 | $82.01 | $53K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 343 | 227 | $11.24 | $3,855 |
| 95251 Test - Miscellaneous | Office | 299 | 146 | $24.06 | $7,195 |
| 83036 Blood Count | Office | 253 | 181 | $9.49 | $2,401 |
| 99211 Office E&M - Established | Office | 166 | 66 | $15.75 | $2,614 |
| 82044 Clinical Chemistry | Office | 53 | 52 | $6.11 | $324 |
| 82570 Clinical Chemistry | Office | 53 | 52 | $5.08 | $269 |
| 99215 Office E&M - Established | Office | 44 | 35 | $121.60 | $5,350 |
| 96372 Injection Administration | Office | 21 | 12 | $10.04 | $211 |
| 82962 Clinical Chemistry | Office | 13 | 13 | $3.21 | $41.73 |
By year: 2022 $85K for 2,411 services; 2023 $92K for 2,712 services; 2024 $101K for 3,160 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 253 | 181 | $9.49 | $2,401 |
| 82044 Clinical Chemistry | 53 | 52 | $6.11 | $324 |
| 82570 Clinical Chemistry | 53 | 52 | $5.08 | $269 |
| 82962 Clinical Chemistry | 13 | 13 | $3.21 | $41.73 |
Medicare prescription drug claims, 2024
In 2024, the drug Paula Szczepanczyk prescribed most often to Medicare patients was Levothyroxine Sodium, with 930 prescriptions and refills. In total Paula Szczepanczyk wrote 7,849 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 930 | 2,311 | 216 | $9,266 |
| Mounjaro Tirzepatide | 605 | 851 | 106 | $882K |
| Ozempic Semaglutide | 490 | 886 | 130 | $829K |
| Atorvastatin Calcium Generic | 315 | 834 | 93 | $2,775 |
| Metformin Hcl Er Metformin Hcl | 274 | 650 | 74 | $2,626 |
| Jardiance Empagliflozin | 268 | 636 | 78 | $363K |
| Humalog Kwikpen U-100 Insulin Lispro | 258 | 642 | 88 | $115K |
| Metformin Hcl Generic | 249 | 665 | 69 | $1,700 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 224 | 645 | 82 | $34K |
| Tresiba Flextouch U-100 Insulin Degludec | 219 | 591 | 70 | $157K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 208 | 527 | 63 | $328K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 189 | 471 | 81 | $26K |
| Trulicity Dulaglutide | 186 | 344 | 50 | $326K |
| Novolog Flexpen Insulin Aspart | 181 | 432 | 62 | $68K |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 163 | 341 | 54 | $19K |
Brand drugs: 4,305 claims; generic drugs: 2,743 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paula Szczepanczyk $118 ($118 in general payments such as food, travel and fees) from 5 companies. The largest payer was Lilly USA, LLC with $47.46.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.